• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by COMPASS Pathways Plc

    4/11/24 4:04:21 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CMPS alert in real time by email
    SC 13G 1 CMPS_SC13G.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    COMPASS PATHWAYS PLC
    (Name of Issuer)

    ORDINARY SHARES, NOMINAL VALUE £0.008 PER SHARE
    (Title of Class of Securities)

    20451W101**
    (CUSIP Number)

    APRIL 2, 2024
    (Date of event which requires filing of this statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         o Rule 13d-1(b)

         þ Rule 13d-1(c)

         o Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).

    ** (See Item 2(e))



                         
    CUSIP No.
     
    20451W101

    SCHEDULE 13G

    Page  
    2
      of   
    11

    1
     NAMES OF REPORTING PERSONS
     
     Integrated Core Strategies (US) LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     3,875,921
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     3,875,921
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     3,875,921
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.7%
    12 TYPE OF REPORTING PERSON

     OO


                         
    CUSIP No.
     
    20451W101

    SCHEDULE 13G

    Page  
    3
      of   
    11

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     3,887,201
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     3,887,201
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     3,887,201
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.7%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    20451W101

    SCHEDULE 13G

    Page  
    4
      of   
    11

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Group Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     3,887,201
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     3,887,201
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     3,887,201
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.7%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    20451W101

    SCHEDULE 13G

    Page  
    5
      of   
    11

    1
     NAMES OF REPORTING PERSONS
     
     Israel A. Englander
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     3,887,201
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     3,887,201
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     3,887,201
    10
     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.7%
    12
     TYPE OF REPORTING PERSON

     IN

                         
    CUSIP No.
     
    20451W101

     SCHEDULE 13G

    Page  
    6
      of   
    11
     
    Item 1.    
     
    (a) Name of Issuer:
     
       
     
      COMPASS Pathways plc (the "Issuer")
     
       
     
    (b) Address of Issuer’s Principal Executive Offices:
     
       
     
     

    33 Broadwick Street
    London W1F 0DQ
    United Kingdom

         
    Item 2.
    (a) Name of Person Filing:
     
    (b) Address of Principal Business Office:
     
    (c) Citizenship:
         
     
      Integrated Core Strategies (US) LLC
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Group Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Israel A. Englander
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: United States
     
       
      (d) Title of Class of Securities:
    ordinary shares, nominal value £0.008 per share ("Ordinary Shares")
     
      (e) CUSIP Number:
    CUSIP number 20451W101 has been assigned to the Issuer’s American Depositary Shares. Each American Depositary Share represents one Ordinary Share. No CUSIP number has been assigned to the Issuer’s Ordinary Shares.
     
     

    Item 3.  If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     
      (a)   o   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
                 
     
      (b)   o   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
                 
     
      (c)   o   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
                 
     
      (d)   o   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
                 
     
      (e)   o   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
                 
     
      (f)   o    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

                         
    CUSIP No.
     
    20451W101

     SCHEDULE 13G

    Page  
    7
      of   
    11
                 
     
      (g)   o   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
                 
     
      (h)   o   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
                 
     
      (i)   o   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
                 
     
      (j)   o   Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4. Ownership

       Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount Beneficially Owned:

       See response to Item 9 on each cover page.

    (b) Percent of Class:   

       See response to Item 11 on each cover page.

     (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote

       See response to Item 5 on each cover page.


                         
    CUSIP No.
     
    20451W101

     SCHEDULE 13G

    Page  
    8
      of   
    11

    (ii) Shared power to vote or to direct the vote

       See response to Item 6 on each cover page.

    (iii) Sole power to dispose or to direct the disposition of

       See response to Item 7 on each cover page.

    (iv) Shared power to dispose or to direct the disposition of

       See response to Item 8 on each cover page.

       The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5. Ownership of Five Percent or Less of a Class

       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o .

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

        Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

        Not applicable.

    Item 8. Identification and Classification of Members of the Group

        See Exhibit I.

    Item 9. Notice of Dissolution of Group

        Not applicable.

    Item 10. Certification 

       By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


                         
    CUSIP No.
     
    20451W101

    SCHEDULE 13G

    Page  
    9
      of   
    11

    Exhibits:

    Exhibit I:  Joint Filing Agreement, dated as of April 10, 2024, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.


                         
    CUSIP No.
     
    20451W101

    SCHEDULE 13G

    Page  
    10
      of   
    11
                         
         

    SIGNATURE

                 

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

    Dated: April 10, 2024

    INTEGRATED CORE STRATEGIES (US) LLC

    By: Integrated Holding Group LP,
           its Managing Member

    By: Millennium Management LLC,
           its General Partner

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander



                         
    CUSIP No.
     
    20451W101

    SCHEDULE 13G

    Page  
    11
      of   
    11
                         
          EXHIBIT I              
                         
          JOINT FILING AGREEMENT              

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Ordinary Shares, nominal value £0.008 per share, of COMPASS Pathways plc will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

    Dated: April 10, 2024

    INTEGRATED CORE STRATEGIES (US) LLC

    By: Integrated Holding Group LP,
           its Managing Member

    By: Millennium Management LLC,
           its General Partner

    By: /s/ Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander


    Get the next $CMPS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CMPS

    DatePrice TargetRatingAnalyst
    6/23/2025$11.00 → $6.00Outperform → In-line
    Evercore ISI
    2/27/2025$11.00Buy
    Stifel
    7/23/2024$23.00Outperform
    RBC Capital Mkts
    4/1/2024$30.00Overweight
    Morgan Stanley
    12/12/2023$16.00Buy
    Deutsche Bank
    11/21/2022$33.00Buy
    Berenberg
    11/1/2022$34.00Buy
    Loop Capital
    11/22/2021$100.00 → $120.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CMPS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025

      Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter ended June 30, 2025, and provide an update on recent developments, on July 31, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on July 31, 2025. A live webcast of the call will be available on the Compass Pathways website at: Second Quarter 2025 Financial Results. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (NASDAQ:

      7/22/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET

      Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat with Patrick Trucchio, Managing Director Equity Research at HC Wainwright at 8:00 am ET on July 14th, 2025. A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in me

      7/10/25 4:00:00 PM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

      A single administration of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS1 with a mean difference of -3.6 comparing 25 mg to placebo (p<0.001)2 Independent Data Safety Monitoring Board (DSMB) reviewed safety data for COMP360 and found no unexpected safety findings and no clinically meaningful imbalance in suicidal ideation between treatment and placebo arms Ongoing pivotal Phase 3 COMP005 trial is the first study of an investigational, synthetic psilocybin, and the first classic psychedelic3, to report Phase 3 efficacy data Second ongoing pivotal Phase 3 COMP006 trial continues to enroll well, wi

      6/23/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • COMPASS Pathways downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded COMPASS Pathways from Outperform to In-line and set a new price target of $6.00 from $11.00 previously

      6/23/25 9:15:38 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on COMPASS Pathways with a new price target

      Stifel initiated coverage of COMPASS Pathways with a rating of Buy and set a new price target of $11.00

      2/27/25 6:17:48 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on COMPASS Pathways with a new price target

      RBC Capital Mkts initiated coverage of COMPASS Pathways with a rating of Outperform and set a new price target of $23.00

      7/23/24 6:23:14 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Santini Gino

      4 - COMPASS Pathways plc (0001816590) (Issuer)

      6/13/25 8:29:43 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Riley Wayne Joseph

      4 - COMPASS Pathways plc (0001816590) (Issuer)

      6/13/25 8:27:48 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Norton David Y

      4 - COMPASS Pathways plc (0001816590) (Issuer)

      6/13/25 8:26:17 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Leadership Updates

    Live Leadership Updates

    See more
    • Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

      Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in underserved communities, if FDA approved. This agreement with HealthPort expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with treatment resistant depression (TR

      4/29/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways appoints Lori Englebert as Chief Commercial Officer

      New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatmentLatest of several key executive team hires, rounding out team to take Compass through phase 3 and beyond LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Lori Englebert as Chief Commercial Officer, effective July 8, 2024. She will be based in the company's New York City office. Lori brings multifaceted experience in global ph

      6/26/24 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways appoints Teri Loxam as Chief Financial Officer

      LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Teri Loxam as Chief Financial Officer (CFO), effective the beginning of March 2024. She will be based in the company's New York City office. Teri will serve as an advisor during the period leading up to her appointment as CFO.  Teri brings to Compass deep and extensive strategic experience working for publicly traded companies, in the pharmaceutical and biotechnology sectors, and beyond. She joins the company from Gameto, where she was CFO and played a

      12/7/23 7:00:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Financials

    Live finance-specific insights

    See more
    • Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025

      Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter ended June 30, 2025, and provide an update on recent developments, on July 31, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on July 31, 2025. A live webcast of the call will be available on the Compass Pathways website at: Second Quarter 2025 Financial Results. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (NASDAQ:

      7/22/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

      Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2025, and provide an update on recent developments, on May 8, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 8, 2025. A live webcast of the call will be available on the Compass Pathways website at: First Quarter 2025 Financial Results. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is

      4/28/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

      Compass management will host a conference call at 8:00 am ET (1:00pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter 2024 ending December 31, 2024, and provide an update on recent developments, on February 27th, 2025. Compass management will host a conference call at 8:00 am ET (1:00pm UK) on February 27, 2025. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on the Compass Pathways website at: F

      2/18/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    SEC Filings

    See more
    • COMPASS Pathways Plc filed SEC Form 8-K: Other Events

      8-K - COMPASS Pathways plc (0001816590) (Filer)

      6/23/25 6:32:31 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by COMPASS Pathways Plc

      8-K - COMPASS Pathways plc (0001816590) (Filer)

      6/13/25 8:14:09 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by COMPASS Pathways Plc

      SCHEDULE 13G - COMPASS Pathways plc (0001816590) (Subject)

      5/15/25 8:00:10 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

      SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

      11/14/24 4:35:16 PM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

      SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

      11/14/24 4:20:24 PM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by COMPASS Pathways Plc

      SC 13G - COMPASS Pathways plc (0001816590) (Subject)

      4/11/24 4:04:21 PM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care